Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Qi, Wei Xiang ^a   Huang, Yu Jing ^a   Yao, Yang ^a   Shen, Zan ^a   Min, Da Liu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; EXEMESTANE; INTERFERON; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PLACEBO; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG FATALITY; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; META ANALYSIS; NEOPLASM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEPSIS; SOLID TUMOR; SUICIDE; SYSTEMATIC REVIEW; TUMOR BLEEDING; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; HUMANS; INCIDENCE; NEOPLASMS; PROTEIN KINASE INHIBITORS; RISK; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84878965833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065166     Document Type: Article

References (59)

1. Fasolo A, Sessa C, (2012) Targeting mTOR pathways in human malignancies. Curr Pharm Des 18: 2766-2777.
2. Brugarolas J, (2007) Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 356: 185-187.
3. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA, (2012) Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17: 69-95.
4. Faivre S, Kroemer G, Raymond E, (2006) Current development of mTOR inhibitors as anticancer agents. Nature Reviews Drug Discovery 5: 671-688.
5. Gnant M, (2012) Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther 12: 1579-1589.
6. Floc'h N, Abate-Shen C (2012) The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer. Oncotarget.
7. Barnett CM, (2012) Everolimus: targeted therapy on the horizon for the treatment of breast cancer. Pharmacotherapy 32: 383-396.
8. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
9. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr, (2003) TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer cell 4: 147-158.
10. Chan S, (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. British journal of cancer 91: 1420-1424.
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
12. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
13. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, et al. (2010) FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15: 428-435.
14. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529.
15. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.
16. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, et al. (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822-3829.
17. Schutz FA, Je Y, Richards CJ, Choueiri TK, (2012) Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30: 871-877.
18. Ranpura V, Hapani S, Wu S, (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
19. Sivendran S, Liu Z, Portas LJ Jr., Yu M, Hahn N, et al. (2012) Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treat Rev.
20. Frost P, Shi Y, Hoang B, Lichtenstein A, (2007) AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26: 2255-2262.
21. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ, (2007) Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26: 611-621.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
23. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
24. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613.
25. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at: http://ctepcancergov/protocolDevelopment/electronic_applications/ctchtm assessed Jan 27 2013.
26. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J, (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28: 2280-2285.
27. Zintzaras E, Ioannidis JP, (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137.
28. Yusuf S, Peto R, Lewis J, Collins R, Sleight P, (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371.
29. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
30. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A, (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19: 1387-1392.
31. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265.
32. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909-918.
33. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, et al. (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23: 5314-5322.
34. Xu B, Wu Y, Shen L, Ye D, Jappe A, et al. (2011) Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol 4: 3.
35. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, et al. (2007) A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2: 1036-1041.
36. Sun Y, Rha S, Lee SH, Guo J, Ueda T, et al. (2012) Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol 42: 836-844.
37. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, et al. (2010) Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16: 5900-5907.
38. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, et al. (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637.
39. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005-2012.
40. Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, et al. (2012) Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 51: 873-879.
41. Matz M, Lehnert M, Lorkowski C, Fabritius K, Unterwalder N, et al. (2012) Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. Transpl Int 25: 1106-1116.
42. Bohler T, Waiser J, Lichter S, Schumann B, Neumayer HH, et al. (2008) Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. Cytokine 42: 306-311.
43. Sawyers C, (2004) Targeted cancer therapy. Nature 432: 294-297.
44. Vignot S, Faivre S, Aguirre D, Raymond E, (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of oncology 16: 525-537.
45. Qi WX, Lin F, Sun YJ, Tang LN, He AN, et al. (2013) Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 71: 431-439.
46. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, et al. (2012) Incidence and Risk of Hypertension with Vandetanib in Cancer Patients: A Systematic review and Meta-analysis of clinical trials. Br J Clin Pharmacol.
47. Chu D, Lacouture ME, Weiner E, Wu S, (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7: 11-19.
48. Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, et al. (2011) Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 43: 286-294.
49. Drucker AM, Wu S, Busam KJ, Berman E, Amitay-Laish I, et al. (2012) Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol.
50. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S, (2012) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11Suppl 1: S9-19.
51. Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, et al. (2012) Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 23: 1943-1953.
52. Assaad U, El-Masri I, Porhomayon J, El-Solh AA, (2012) Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 7: 453-461.
53. Willcocks LC, Chaudhry AN, Smith JC, Ojha S, Doffinger R, et al. (2007) The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant 7: 2006-2011.
54. MacDonald AS, (2003) Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 35: 201S-208S.
55. Trotter JF, (2003) Sirolimus in liver transplantation. Transplant Proc 35: 193S-200S.
56. Champion L, Stern M, Israel-Biet D, Mamzer-Bruneel MF, Peraldi MN, et al. (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144: 505-509.
57. Lindenfeld JA, Simon SF, Zamora MR, Cool CD, Wolfel EE, et al. (2005) BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant 5: 1392-1396.
58. Manito N, Kaplinsky EJ, Bernat R, Roca J, Castells E, et al. (2004) Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 23: 780-782.
59. Kahan BD, (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356: 194-202.